Clinical trial · no report yet · Phase 3
ZUMA-23
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- NCT05605899 ↗
- Active not recruiting
- Kite, A Gilead Company
- 63 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 32 | |
| Podcasts | 20 | |
| X threads | 11 |
The trial
ClinicalTrials.gov- Official title
- An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Etoposide; Rituximab; Doxorubicin; Vincristine; Prednisone
- Arms
- Axicabtagene Ciloleucel · Experimental
- Standard of Care Therapy · Active comparator
- Enrollment
- 300 (estimated)
- Primary outcomes
- Event-free Survival (EFS) by Blinded Central Assessment
- Sponsor
- Kite, A Gilead Company
- Start
- Feb 10, 2023
- Primary completion
- Mar 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05605899 · updated Apr 15, 2026